reactivation is commonly reported in patients receiving anticancer therapy, immunosuppressive therapy, or organ and tissue transplantation. However, the precise mechanisms underlying chemotherapeutic agent-related HBV reactivation remain unclear. Here, we report that peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α) plays a central role in cisplatininduced HBV transcription and replication. First, cisplatin treatment upregulated the expression levels of PGC-1α and hepatocyte nuclear factor 4 alpha (HNF-4α) in both HBV-replicating cells and an HBVtransgenic mouse model. PGC-1α coactivates with HNF-4α, which interacts with a core promoter and enhancer II region of HBV genome, thereby promoting HBV production. In contrast, knockdown of PGC-1α and HNF-4α by RNA interference in hepatoma cells reversed HBV activation in response to cisplatin. Additionally, PGC-1α upregulation depended on cisplatin-mediated endoplasmic reticulum (ER) stress. We further observed that the recruitment of cyclic AMP-responsive element-binding protein plays a crucial role for PGC-1α transcriptional activation in cisplatin-treated cells. Finally, pharmacologic inhibition of ER stress impaired PGC-1α upregulation and HBV production induced by cisplatin treatment. These findings demonstrate novel molecular mechanisms indicating that ER stress-PGC1α signaling pathway plays a critical role in cisplatin-evoked HBV reactivation.
Results
Cisplatin directly upregulates HBV replication in HBV-expressing liver cells. We previously found that epirubicin and vincristine directly promoted HBV replication in stable HBV-expressing hepatoma cells 19, 20 . In this study, we first explored whether other cytotoxic chemotherapy agents could directly upregulate HBV replication in vitro, in the context of hepatoma or hepatocytes expressing HBV without an innate and adaptive immune system. Stable HBV-expressing cell line HepAD38 and HepG2-HBV1.1 cells were treated with the optimal dose of chemotherapy agents ( Supplementary Fig. 1a ). We found that cytotoxic chemotherapy induces a sharp increase in HBV DNA levels ( Fig. 1a ). Primary hepatocytes, derived from an HBV replication mouse model including transgenic mice and hydrodynamic injection mouse model, were used to examine the effects of cytotoxic agents on HBV replication. An approximately 10-40-fold induction of HBV DNA levels was observed in primary hepatocytes derived from HBV-Tg mice and hydrodynamic mouse model after treatment with chemotherapy agents for 5 days. Among the cytotoxic agents, cisplatin displayed the strongest stimulatory effects (Fig. 1b ). Consequently, cisplatin was chosen as the representative chemotherapy agent for the experiments. Treatment with 6 μM cisplatin significantly increased both intracellular and secreted HBV DNA levels ( Fig. 1c) , which was confirmed by Southern blot analysis (Fig. 1d ). Moreover, cisplatin treatment enhanced HBV replicative intermediates and increased HBV 3.5 kb mRNA, intracellular HBsAg and HBcAg expression, and HBeAg levels in the culture supernatants ( Fig. 1e-g) . In addition, similar enhanced HBV replication was examined by cisplatin treatment in HBV-infected HepG2-NTCP cells ( Supplementary Fig. 1b,c) . When cells were pretreated with nucleotide analogue inhibitors, including lamivudine and entecavir, cisplatin-mediated upregulation of HBV replication was not impaired when comparing PBS treatments ( Supplementary Fig. 1d,e ). The aforementioned results suggested that chemotherapy agents, especially cisplatin, strengthen HBV replication and transcription in HBV-expressing liver cells.
Cisplatin treatment enhances HBV replication in the HBV mouse model. We investigated whether cisplatin could strengthen HBV replication in the HBV mouse model. Six HBV-Tg mice or mice that received HI of pHBV1.3 were treated with 6 mg/kg cisplatin or phosphate-buffered saline (control) for 5 days. We found that cisplatin administration significantly increased serum HBsAg, HBeAg, and HBV DNA levels by approximately 1.5-, 2.5-, and 30-fold, respectively, in the hydrodynamic HBV mouse model ( Fig. 2a,b; Supplementary Fig. 2a ). Consistently, HBV DNA levels, HBV replication intermediates in the liver, HBV 3.5 kb mRNA, and HBsAg and HBcAg in hepatocytes were markedly enhanced after cisplatin administration ( Fig. 2c-f ; Supplementary  Fig. 2b,c) . Similarly, HBV replication enhancement was observed in cisplatin-treated HBV-Tg mice (Fig. 2) . Previous studies reported that HBV reactivation with chemotherapy usually evokes moderate or severe liver damage in patients 14, 15 . To determine whether cisplatin treatment could induce liver injury, we assessed serum ALT activity levels and histopathological lesions after cisplatin treatment. Serum ALT was elevated by approximately 2and 1.8-fold in the HI mouse model and HBV-Tg mouse model, respectively ( Fig. 2a ). An apparent inflammatory SCIENTIFIC REPORTS | (2018) 8:3496 | DOI:10.1038/s41598-018-21847-3 cell infiltration in the portal area was easily observed in the cisplatin-treated HBV mouse model (Fig. 2d ). These results indicated that cisplatin treatment augments HBV DNA replication in the HBV mouse model.
Cisplatin augments viral HBV transcription through HNF-4α and PGC-1α activation.
We investigated the mechanism in HBV replication due to cisplatin administration. We found that cisplatin treatment significantly increased the core promoter activity by approximately three-fold and activated preS1 and preS2 promoters activity with much less efficiency ( Fig. 3a ). Host factors, especially numerous transcription factors, can stimulate or suppress HBV genome transcription and replication. To identify the transcription factors involved in HBV activation by cisplatin, a real-time PCR assay was performed. The mRNA and protein levels of HNF-4α and PGC-1α were robustly upregulated in HBV-expressing cells following cisplatin treatment ( Fig. 3b , Supplementary Fig. 3a ).
Subsequently, HNF-4α and PGC-1α was depleted via shRNA treatment, and the effects of cisplatin on viral DNA replication in vitro and in HBV-Tg mice were examined. As anticipated, induction of viral DNA replication following cisplatin treatment was strikingly reduced by treatment with siPGC-1α or siHNF-4α alone, with stronger inhibitory efficacy in PGC-1α-depleted cells. Combined treatment using siHNF-4α and siPGC-1α has the most inhibitory effects ( Fig. 3c-f ), indicating that HNF-4α and PGC-1α are vital for cisplatin-stimulated viral DNA replication. Moreover, knockdown of HNF-4α and PGC-1α similarly abolished cisplatin-mediated HBV transcription and viral protein production in HBV-Tg mouse ( Fig. 4a-e ).
HBV transcription is regulated by HNF-4α and the transcription coactivator PGC-1α, which binds to nuclear receptor response elements mainly found in its two enhancers 21 ( Supplementary Fig. 3b ). Thus, whether PGC-1α and HNF-4α are directly responsible for cisplatin-enhanced viral transcription was addressed. Chromatin immunoprecipitation experiments were performed using antibodies against HNF-4α and PGC-1α, and cisplatin treatment was found to enhance recruitment of HNF-4α and PGC-1α to the HNF-4α binding site on Enh II ( Supplementary Fig. 3c,d ). However, silencing of HNF-4α and PGC-1α robustly impaired the binding capacity when siRNA was introduced to HBV-expressing cells (Fig. 3g ). Generally, these results strongly indicated that cisplatin is a positive regulator for endogenous HNF-4α and PGC-1α expression, and HNF-4α and coactivator PGC-1α activation on the core promoter plays a significant role in cisplatin-triggered HBV synthesis.
ER stress is required for cisplatin-induced HBV transcription.
Previous studies showed that cisplatin treatment induces ER stress in hepatoma cells, and ER stress can activate cyclic AMP (cAMP)-responsive element-binding protein (CREB), which modulates PGC-1α transcription [22] [23] [24] . Our results showed that knockdown of PGC-1α demonstrated more inhibitory effects on cisplatin-stimulated HBV synthesis. Based on our results, we hypothesized that cisplatin-induced ER stress may mediate PGC-1α upregulation in a CREB-dependent manner.
First, the effects of cisplatin treatment were tested on ER stress response element-mediated transcriptional activity. Treatment with thapsigargin (Tg), an ER stress inducer, increased pERSE luciferase signalling in HepAD38 cells by approximately 2.5-fold compared with PBS control. Cisplatin treatment increased pERSE luciferase signalling by 1.5-fold compared with that in untreated cells ( Fig. 5a ). ER stress can activate UPR through three main signalling arms: IRE1, ATF6, and PERK. We accordingly examined which of these arms were activated in HepAD38 or HepG2.2.15 cells by cisplatin treatment and found that cisplatin increased the mRNA levels of phosphorylated IRE1, PERK, and ATF6 pathways ( Fig. 5b; Supplementary Fig. 4a ). Similarly, protein levels of spliced XBP-1s, CREB-1, and GRP78/BiP were robustly upregulated (2-, 2.5-, and 5-fold in HepAD38 and 2.2-, 1.8-, and 7.5-fold in HepG2.2.15 cells, respectively, compared to the PBS control) ( Fig. 5c ; Supplementary  Fig. 4b,c ). These data indicated that cisplatin activates each of the UPR branches, and phosphor-CREB protein was robustly elevated by cisplatin and Tg treatment, along with the increased protein and mRNA levels of PGC-1α. Therefore, cisplatin-induced PGC-1α upregulation by CREB phosphorylation is ER stress dependent. We further validated whether ER stress inhibition can reverse cisplatin-induced upregulation of PGC-1α. 4-PBA and specific IRE1 inhibitor (4 μ8C) 25 were used as ER stress inhibitors. Cisplatin-induced activation of ER stress markers was markedly reduced by PBA and 4 μ8C. Furthermore, the mRNA levels of both CREB and PGC-1α were significantly reduced, indicating the involvement of ER stress in cisplatin-mediated PGC-1α expression regulation ( Fig. 5c ; Supplementary Fig. 4c ).
To quantify the effects of cisplatin on PGC-1α transcriptional activity, HepAD38 cells were transfected with PGC-1α-luc reporter plasmid containing a luciferase ORF under the PGC-1α promoter. The data indicated that cisplatin treatment substantially induced PGC-1α promoter activity, whereas ER stress response inhibition by PBA or 4 μ8C significantly reduced cisplatin-provoked luciferase activity by approximately 70% (Fig. 5d ). Moreover, chromatin immunoprecipitation assay revealed that ER stress inhibition significantly decreased CREB recruitment to the PCG-1α promoter ( Fig. 5e; Supplementary Fig. 4d ). These findings indicated that cisplatin upregulates PGC-1α expression via ER stress signal activation.
Cisplatin-induced endogenous PGC-1α through ER stress supports HBV transcription.
Whether cisplatin-induced PGC-1α upregulation and HBV activation are dependent on ER stress response was investigated. ER stress inhibition with PBA or 4 μ8C was found to substantially suppress cisplatin-enhanced HBV transcription and HBeAg and HBsAg production ( Fig. 6a,b ; Supplementary Fig. 5a,b) . Moreover, treatment with thapsigargin (ER stress inducer) alone also enhanced HBV replication and transcription through induction of ER stress. However, ER stress inhibitor-PBA strongly blocked Tg-induced HBV activation (Fig. 6a ). In addition, treatment with ER stress inhibitor combined with cisplatin, cccDNA levels, 3.5-kb mRNA levels, and HBV DNA intermediates in HepAD38 cells, and HepG2-HBV1.1 cells sharply decreased compared with those with cisplatin treatment only ( Fig. 6c to f; Supplementary Fig. 5c-e ).
Furthermore, whether HBV transcription is affected by ER stress inhibitor administration in vivo ( Supplementary Fig. 6a ) was validated. Cisplatin administration resulted in a significant HBV replication and HBsAg antigenemia. Treatment with ER stress inhibitor, PBA, or 4 μ8C via intraperitoneal administration substantially decreased serum HBeAg, HBsAg, HBV DNA, and ALT levels compared with cisplatin treatment alone ( Supplementary Fig. 6b-e ). Analysis of liver samples revealed that the induction of DNA replication, protein synthesis, and liver injury by cisplatin was remarkably reduced when ER stress inhibitor was co-administered. Moreover, combined treatment with ER stress inhibitor and cisplatin remarkably reversed cisplatin-induced expression of phosphorylated CREB-1, IRE1, and PGC-1α ( Fig. 7a-e ). These results suggested that cisplatin activates HBV replication possibly by HBV DNA-associated PGC-1α activation through ER stress response.
Discussion
HBV reactivation is most commonly reported in patients undergoing anticancer therapy, immunosuppressive therapy, or organ and tissue transplantation. Recently, HBV reactivation has also been reported to occur in chronic hepatitis C (CHC) patients co-infected with HBV receiving direct-acting antiviral therapy 26, 27 . Immune system reconstitution after the completion of chemotherapeutic or immunosuppressive therapy plays a central role in HBV reactivation and liver injury. However, the mechanism for the enhanced viral replication during cytotoxic chemotherapy remains unclear. In this study, we provide novel evidence that ER stress-PGC-1α signalling pathway is a critical regulator of cisplatin-induced HBV transcription and replication. Inhibition of the ER stress-PGC-1α pathway significantly blocked the stimulatory activity of cisplatin on HBV replication both in HBV-replicative hepatoma cells and in HBV-transgenic mouse model.
Our findings demonstrated that cisplatin strengthens HBV replication through upregulation of HNF-4α and PGC-1α expression. HBV is a double-stranded DNA virus that replicates by reverse transcription. Several transcription factors bound to the HBV core promoter are responsible for the transcription of HBV 3.5 kb mRNA, which plays a pivotal role in the HBV life cycle. Previous studies reported that doxorubicin and other chemotherapeutic medications enhanced HBV replication in HBV-expressing hepatoma cells 18 . Doxorubicin induced P21(Waf1/Cip1) expression and enhanced the binding of CCAAT/enhancer-binding protein α to the HBV core promoter, thereby contributing to enhanced HBV replication 28 Recently, Mouler Rechtman M et al. reported that anticancer cytotoxic agents induce PGC-1α upregulation and coactivate HBV transcription 29 . Our results are consistent with previous findings that chemotherapeutic agents directly stimulate HBV replication through activation of the transcriptional factors HNF-4α and PGC-1α.
Potential HBV reactivation is associated with the persistence in the nucleus of infected hepatocytes of a stable HBV cccDNA 30, 31 , which serves as the template for all HBV mRNA syntheses. High levels of post-transcriptional modification similar to chromosomal DNA results in active transcription of HBV DNA. HBx protein is reported to activate HBV transcription by recruitment of p300 and CBP acetyltransferase onto cccDNA 32 . Recently, protein arginine methyltransferase 5 induced epigenetic suppression of cccDNA transcription and interfered with pgRNA encapsidation 33 . Moreover, interferon-Iα or interleukin-6 treatment reduced active epigenetic modification of cccDNA and suppressed HBV transcription 34, 35 . Our study showed that, besides HBV transcription level, both HBV cccDNA and 3.5-kb mRNA levels were enhanced by cisplatin. Liver-enriched transcription factors, such as HNF4 and retinoid X receptor α (RXRα), are capable of binding to cccDNA and contribute to the efficient cccDNA transcription 36 . Future studies are necessary to explore whether host factors and epigenetic regulators are involved in cisplatin-induced upregulation of cccDNA and 3.5 kb mRNA levels.
Another key finding of this study is that cisplatin could increase HBV core promoter activity and virus replication via enhancement of the metabolism regulator PGC-1α. Previous studies indicated that PGC-1α is a critical regulator in both HBV biosynthesis and gluconeogenesis 37, 38 . An early study showed that PGC-1α coactivates HNF-4α to enhance HBV replication through nutritional signals 39 . PGC-1α activation by CREB is a common pattern in liver gluconeogenesis. Our results demonstrated that cisplatin induces CREB-PGC-1α activation and enhances HBV replication, indicating that HBV hijacks the energetic pathway for its production under certain SCIENTIFIC REPORTS | (2018) 8:3496 | DOI:10.1038/s41598-018-21847-3 environmental stress. HBV may tune in virus biosynthesis and protein production adaptive to external metabolic signal or physiological stress 40 . These data, combined with our results, suggest that the regulation of viral replication and metabolism might adopt similar hepatic signal transduction pathways. Interestingly, our results also demonstrated that other transcription factors such as CREB and RXRα were upregulated after cisplatin treatment. Except for an activator for PGC-1α transcription, CREB may bind to HBV core promoter and directly stimulate viral transcription. We speculated that other factors aside from ER stress and PGC-1α upregulation may also be involved in cisplatin-mediated HBV activation, which remains to be further studied. Another limitation of this study is that the replication status of HBV in our experiment model is distinct from that in clinical patients. In an HBV-replicating cell model or HBV mouse model, the replication levels of HBV are relatively high, but viral replication is negative or very low in clinical patients before HBV reactivation. Thus, cisplatin-induced HBV activation needs to be confirmed in more relevant models or in patients.
Importantly, we propose a model that illustrates the molecular mechanism underlying cisplatin-induced HBV activation. In this model, cisplatin upregulates PCG-1α through an ER stress-mediated, phosphorylated CREB-dependent pathway. Cisplatin induces ER stress and adaptive UPR activation in HBV replicative cells. IRE1, an arm of the UPR pathway, activates CREB-1 phosphorylation and upregulates PGC-1α expression. As an HBV transcription coactivator, PGC-1α indirectly binds to the HBV core promoter region through interaction with HNF4α. Lastly, inhibition of ER stress, IRE1 pathway, or PGC-1α expression rendered cisplatin-induced HBV biosynthesis in vitro and in vivo (Fig. 7f) . The therapeutic potential of PGC-1α modulators or ER stress inhibitors have been demonstrated in an animal model 41 ; hence, novel potential therapeutic strategies should target PGC-1α or ER stress for the treatment of chemotherapy-related HBV reactivation.
Methods

Cell cultures, transfection, in vitro viral infection, and chemotherapy. The stable HBV-expressing
cell lines HepG2-HBV1.1 and HepAD38 cells were cultured and transfected using Lipofectamine TM 2000 (Invitrogen, Carlsbad, CA, USA) as previously described 42 . HepG2-HBV1.1 cells were maintained in Dulbecco's modified Eagle medium (DMEM, HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, Rockville, MD, USA), 100 units/mL penicillin, and 100 μg/mL streptomycin (HyClone). HepAD38 cells were cultured in DMEM/F-12 medium containing 400 ng/ml tetracycline to suppress HBV pgRNA transcription. At 7 days after tetracycline removal, HepAD38 cells were treated with chemotherapeutic agents.
HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide (HepG2-NTCP) were infected with HBV virus as described previously 43, 44 . Briefly, the cell culture medium of HepAD38 cells was filtered through a 0.45-μm filter and precipitated with 8% PEG8000 overnight at 4 °C. After precipitation, the concentrated HBV particles were used to infect HepG2-NTCP cells in the presence of 4% PEG8000 for 24 h.
For chemotherapy treatment, cells were incubated with 6 μM cisplatin (Nanjing Pharmaceutical Factory Co., Ltd., Jiangsu, China), 0.3 μM vincristine (Guangdong Lingnan Pharmaceutical Co., Ltd., Guangdong, China), or 0.6 μM epirubicin (Hisun Chemical Co., Ltd., Zhejiang, China) for 96 h. The medium was replaced with fresh . ER stress inhibitors alleviate cisplatin-induced HBV reactivation in HBV transgenic mouse model. HBV transgenic mice were randomly divided into four groups (n = 6 for each group). Animals received 100 mg/kg PBA or 10 mg/kg 4 μ8C for 1 day, followed by treatment with PBA or 4 μ8C combined with 6.0 mg/kg cisplatin daily for 5 days. On the sixth day, the mice were sacrificed and serum and tissue samples were collected. serum-free DMEM medium for an additional 48-h incubation, and the cells were collected for detection. For ER stress induction, cells were treated with 100 nM ER stress inducer thapsigargin for 8 h and subsequently collected for analysis.
Antibodies and reagents. The following primary antibodies were used for the western blot analysis:
anti-PGC-1α (no. sc-13067), anti-HNF-4α (no. sc-374229), and anti-pCREB-1 antibodies (no. sc-81486), which were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies to GRP78/BiP (no. ab32618), phosphor-IRE1(no. ab48187), and CREB-1 (no. ab32515) were obtained from Abcam (Cambridge, UK). Antibodies to IRE1α (no. 3294 P) and PERK (5683 P) were obtained from Cell Signaling Technology (Danvers, MA, USA). Anti-HBcAg (no. B0586), anti-HBsAg (no. NB100-62652), and anti-XBP-1s (no. 647501) antibodies were obtained from Dako (Dako, Glostrup, Denmark), Novus Biological (Littleton, CO, USA), and BioLegend (San Diego, CA, USA), respectively. IRE1 inhibitor 4-methylumbelliferone 8-carbaldehyde (4 μ8C, no. S7272) was obtained from Selleck Chemicals (Houston, TX, USA). 4-Phenylbutyric acid (PBA, no. P21005), thapsigargin (Tg, no. T9033), and lamivudine (LMV, no. Y0000426) were obtained from Sigma-Aldrich (St Louis, USA). Entecavir (ETV, no. 003) was obtained from Yingxuan Chempharm Co., LTD (Shanghai, China).
Adenoviruses and reporter plasmids. Oligonucleotides containing siRNA target sites for the coding region of human or mouse HNF-4α and PGC-1α (Supporting Table S1 ) were annealed and subcloned into the Sfi I site of pSES vector (from Dr. T-C He, University of Chicago). The shuttle vectors were used to generate adenovirus AdR-siSnail using the AdEasy system 45 . The resultant adenoviral vector also expresses monomeric red fluorescent protein (RFP).
An ER stress reporter plasmid that contains a common motif of upstream ER stress response elements (pERSE-luc) was purchased from Beyotime Institute of Biotechnology, Shanghai, China 46 . The PGC-1α promoter-luciferase reporter was generated by cloning ~1 kb polymerase chain reaction (PCR) fragment into the pGL3-basic vector (Promega, Madison, WI, USA; #E1751).
Primary hepatocyte isolation.
Primary mouse hepatocytes were isolated by a conventional two-step collagenase perfusion method as described previously 47 .
Cell Viability Assays. Cell viability was assessed by trypan blue staining assay. Cells were seeded in 24-well plates followed by exposure to medium containing phosphate-buffered saline (PBS) or the indicated concentration of cisplatin for 5 days. For trypan blue staining, adherent cells were collected and stained with 0.4% trypan blue (Beyotime, Nantong, China) for 5 min at 37 °C. The number of cells excluding trypan blue was counted in a hemocytometer and expressed as a percentage of viable cells compared with PBS-treated cells.
Western blot analysis. Whole protein lysates were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and electrotransferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The blots were probed with the indicated antibodies. The secondary antibodies coupled to horseradish peroxidase were purchased from Abcam (Cambridge, UK). Protein bands were visualized with SuperSignal West Pico Chemiluminescent Substrate Kits (Millipore).
Animal models. Hydrodynamic injection (HI) experiments were performed as described previously 48 . C57BL/6 J mice (6-8 weeks old, 6 mice per group) were provided by the Laboratory Animal Center of Chongqing Medical University (SCXK (YU) 2012-0001). Mice were treated daily with 6.0 mg/kg cisplatin or phosphate-buffered saline (PBS) control via tail vein injection for 5 days, after HI of HBV replication-competent plasmid pHBV1.3. For siRNA experiments, 10 μg of pHBV1.3 and AdR-siPGC-1α, AdR-siHNF-4α, or AdR-sicontrol were co-administered into the mice.
HBV-transgenic (HBV-Tg) mice (n = 6 for each group, kindly provided by Prof. Ning-shao Xia from the School of Public Health, Xiamen University) 49 were intraperitoneally injected with 10.0 mg/kg 4-methylumbelliferone 8-carbaldehyde (4 μ8c),100 mg/kg phenylbutyric acid (PBA), or PBS control for 1 day, followed by treatment with 6.0 mg/kg cisplatin daily for five days. At the sixth day post-injection, the mouse serum and liver tissue samples were evaluated.
Ethics Statement. The protocol for the use and care of animals was approved by the Institutional Animal Care and Use Committee at Chongqing Medical University (the project license number: 2014051). All mice were maintained under specific pathogen-free conditions in the laboratory animal center of Chongqing Medical University. Animal care and use protocols adhere to National Regulations for the administration of laboratory animal.
Quantification of HBV DNA and cccDNA level by real-time polymerase chain reaction. Viral
DNAs were precipitated with 35% PEG8000 and isolated from cytoplasmic core particle preparations by proteinase K digestion followed by phenol/chloroform extraction as described previously 31 . For cccDNA detection, the DNA samples were first pretreated with Plasmid-Safe DNase (Epicenter, Madison, WI). The extracted nuclear DNA was then analysed for cccDNA using TaqMan probe by real-time PCR with the indicated primers ( Supplementary Table S1 ). The precipitated core particle DNA was measured by quantitative PCR or Southern blot. The plasmid pCH9/3091(containing 1.1 copies of HBV genome) served as a template for the standard curve. Southern blot analysis. The total HBV DNA was extracted from hepatoma cells or liver samples using the Wizard ® Genomic DNA Purification Kit (Promega) and analysed by Southern blotting using a digoxigenin-labelled HBV-specific probe, as described previously 42 .
Detection of HBV antigen, HBV DNA, and alanine aminotransferase in the mouse sera. Serum
HBsAg and HBcAg levels in the mouse serum were determined with the commercially available radioimmunoassay kits (Beijing North Biotechnology Research Institute, Beijing, China). HBV DNA levels were quantified by a real-time PCR using SYBR Green dye as described previously 42 . Serum ALT was assayed with ELISA Kit (Bogoo Bio-Tech Co. Ltd, Shanghai, China), according to the manufacturer's instructions.
Immunohistochemistry. Paraffin-embedded liver tissue sections were stained with mouse anti-HBsAg antibody (ab20402, Abcam) or rabbit anti-HBcAg antibody (B0586, DAKO). Subsequently, tissue sections were incubated with Envision System and visualized using DAB substrate (Maixin-Bio, Fuzhou, China), according to the manufacturer's instructions. IHC staining was quantitatively analysed using Image Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA).
RNA isolation and real-time PCR.
Total RNA was isolated using TRIzol (Invitrogen, Rockville, MD) following the manufacturer's instructions. cRNA served as a template to prepare a second round of cDNA using Moloney murine leukaemia virus reverse transcriptase (Promega). SYBR Green-based quantitative PCR analysis was performed using iQ5 real-time PCR detection system (Bio-Rad, CA, USA). HBV 3.5 kb mRNA quantification is normalized to genomic beta-actin. The primer sequences used for PCR are listed in Supplementary Table S1 .
Chromatin immunoprecipitation analysis. Chromatin immunoprecipitation analysis was performed as described previously 45 . Briefly, sonicated cell lysates were subjected to immunoprecipitation using 5 µg of the respective primary antibody (normal IgG served as control). Following elution, DNA was extracted and subjected to PCR analysis. Primers specific for the human PPARGC1A (PGC1a) promoters or HBV Enh II region (nt1650-nt1775) were used for PCR amplification (S1 Table) . For chromatin immunoprecipitation-quantitative PCR, the immunoprecipitated DNA was quantitated by real-time PCR. Transcription factor enrichment was quantitated relative to the input control.
Statistical analysis.
All values were presented as means ± standard deviation (SD). Statistical significance was determined using one-way analysis of variance for multiple comparisons, and Student's t-test was used to compare two groups. Probability values (p) <0.05 were considered statistically significant. Data Availability. All data generated or analysed during this study are included in this published article (and its Supplementary Information files).
